Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study

被引:41
|
作者
van Dijkhuizen, Evert Hendrik Pieter [1 ,5 ]
Calasan, Maja Bulatovic [1 ]
Pluijm, Saskia M. F. [2 ]
de Rotte, Maurits C. F. J. [3 ]
Vastert, Sebastiaan J. [1 ]
Kamphuis, Sylvia [4 ]
de Jonge, Robert [3 ]
Wulffraat, Nico M. [1 ]
机构
[1] Wilhelmina Childrens Hosp, Univ Med Ctr Utrecht, Dept Paediat Immunol, Utrecht, Netherlands
[2] Erasmus Univ, Sophia Childrens Hosp, Med Ctr Rotterdam, Dept Paediat Haematooncol, Rotterdam, Netherlands
[3] Erasmus Univ, Med Ctr Rotterdam, Dept Clin Chem, Rotterdam, Netherlands
[4] Erasmus Univ, Med Ctr Rotterdam, Sophia Childrens Hosp, Dept Paediat Rheumatol, Rotterdam, Netherlands
[5] IRCCS G Gaslini, Reumatol, Pediat 2, I-16147 Genoa, Italy
关键词
Juvenile idiopathic arthritis; Methotrexate; Adverse events; Methotrexate intolerance; Prediction model; Predictor; RHEUMATOID-ARTHRITIS; ADVERSE EVENTS; FOLATE PATHWAY; FOLINIC ACID; MTX TOXICITY; POLYMORPHISMS; EFFICACY; CHILDREN; ASSOCIATION; VALIDATION;
D O I
10.1186/s12969-015-0002-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Methotrexate (MTX) is an effective and safe drug in the treatment of juvenile idiopathic arthritis (JIA). Despite its safety, MTX-related gastrointestinal adverse effects before and after MTX administration, termed MTX intolerance, occur frequently, leading to non-compliance and potentially premature MTX termination. The aim of this study was to construct a risk model to predict MTX intolerance. Methods: In a prospective JIA cohort, clinical variables and single nucleotide polymorphisms were determined at MTX start. The Methotrexate Intolerance Severity Score was employed to measure MTX intolerance in the first year of treatment. MTX intolerance was most prevalent at 6 or 12 months after MTX start, which was defined as the outcome for the prediction model. The model was developed in 152 patients using multivariable logistic regression analysis and subsequently internally validated using bootstrapping. Results: The prediction model included the following predictors: JIA category, antinuclear antibody, parent/patient assessment of pain, Juvenile Arthritis Disease Activity Score-27, thrombocytes, alanine aminotransferase and creatinine. The model classified 77.5% of patients correctly, and 66.7% of patients after internal validation by bootstrapping. The lowest predicted risk of MTX intolerance was 18.9% and the highest predicted risk was 85.9%. The prediction model was transformed into a risk score (range 0-17). At a cut-off of >= 6, sensitivity was 82.0%, specificity 56.1%, positive predictive value was 58.7% and negative predictive value 80.4%. Conclusions: This clinical prediction model showed moderate predictive power to detect MTX intolerance. To develop into a clinically usable tool, it should be validated in an independent cohort and updated with new predictors. Such an easy-to-use tool could then assist clinicians in identifying patients at risk to develop MTX intolerance, and in turn to monitor them closely and intervene timely in order to prevent the development of MTX intolerance.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Prediction of Methotrexate Intolerance in Juvenile Idiopathic Arthritis: a prospective, observational cohort study
    Evert Hendrik Pieter van Dijkhuizen
    Maja Bulatović Ćalasan
    Saskia MF Pluijm
    Maurits CFJ de Rotte
    Sebastiaan J Vastert
    Sylvia Kamphuis
    Robert de Jonge
    Nico M Wulffraat
    Pediatric Rheumatology, 13
  • [2] Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study
    van Dijkhuizen, Evert H. Pieter
    Aidonopoulos, Orfeas
    ter Haar, Nienke M.
    Marafon, Denise Pires
    Magni-Manzoni, Silvia
    Loannidis, Yannis E.
    Putignani, Lorenza
    Vastert, Sebastiaan J.
    Malattia, Clara
    De Benedetti, Fabrizio
    Martini, Alberto
    RHEUMATOLOGY, 2018, 57 (10) : 1752 - 1760
  • [3] HOW COMMON IS METHOTREXATE INTOLERANCE IN JUVENILE IDIOPATHIC ARTHRITIS?
    Khan, Mohammad Saad
    Pijoan-Moratalla, Cristina
    Lee, Martin A.
    RHEUMATOLOGY, 2019, 58
  • [4] Methotrexate intolerance in oral and subcutaneous administration in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
    van Dijkhuizen, E. H. P.
    Pouw, J. N.
    Scheuern, A.
    Huegle, B.
    Hardt, S.
    Ganser, G.
    Kuemmerle-Deschner, J. B.
    Horneff, G.
    Holzinger, D.
    Calasan, M. Bulatovic
    Wulffraat, N. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (01) : 148 - 154
  • [5] Methotrexate Intolerance in Patients with juvenile idiopathic Arthritis - Frequency and Countermeasures
    Scheuern, A.
    Haas, J.
    Huegle, B.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 81 - 81
  • [6] Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management
    Wibrand, Camilla
    Kyvsgaard, Nini
    Herlin, Troels
    Glerup, Mia
    PEDIATRIC DRUGS, 2024, 26 (05) : 479 - 498
  • [7] Intolerance in oral versus subcutaneous administration of methotrexate in patients with juvenile idiopathic arthritis: a cross-sectional, observational study
    Pieter Van Dijkhuizen
    Juliëtte Pouw
    Andrea Scheuern
    Boris Hügle
    Sven Hardt
    Gerd Ganser
    Jasmin Beate Kümmerle-Deschner
    Gerd Horneff
    Dirk Holzinger
    Maja Bulatović Ćalasan
    Nico Wulffraat
    Pediatric Rheumatology, 12 (Suppl 1)
  • [8] High Prevalence of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Development and Validation of a Methotrexate Intolerance Severity Score
    Bulatovic, Maja
    Heijstek, Marloes W.
    Verkaaik, Marleen
    van Dijkhuizen, E. H. Pieter
    Armbrust, Wineke
    Hoppenreijs, Esther P. A.
    Kamphuis, Sylvia
    Kuis, Wietse
    Egberts, Toine C. G.
    Sinnema, Gerben
    Rademaker, Carin M. A.
    Wulffraatl, Nico M.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (07): : 2007 - 2013
  • [9] Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study
    Giorgia Martini
    Alessandra Meneghel
    Michele Fastiggi
    Filippo Dell’Apa
    Fabio Vittadello
    Francesco Zulian
    Pediatric Rheumatology, 21
  • [10] Strategic use of levofolinic acid for methotrexate-induced side effects in juvenile idiopathic arthritis: a prospective observational study
    Martini, Giorgia
    Meneghel, Alessandra
    Fastiggi, Michele
    Dell'Apa, Filippo
    Vittadello, Fabio
    Zulian, Francesco
    PEDIATRIC RHEUMATOLOGY, 2023, 21 (01)